YAP1 and cancer: The coupling of PD-L1 and HIF/YAP/Notch signaling has led to a proposed idea that the targeting therapy on HIF/YAP/Notch signaling pathways, along with the conventional chemotherapy and immune therapy, might serve as a potential surrogate for cancer treatment (Janghorban et al., 2018) (Module Box VI).